Interleukin-2 receptor-targeted fusion toxin: Began Phase II trial of three dose levels and placebo in 60 patients. Doses will be given three times a week for f

Seragen Inc. (SRGN), Hopkinton, Mass.
Product: Interleukin-2

Read the full 70 word article

How to gain access

Continue reading with a
two-week free trial.